MEDIPOST enters into new business and accelerates its clinical trials in the U.S. through third-party allotment financing2022/03/17MEDIPOST
MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”2021/04/02MEDIPOST
MEDIPOST enters an agreement with LG Chem to transfer its MLSC technology, a next-generation cell culture platform technology, to develop gene and cell therapy products2020/12/23MEDIPOST
MEDIPOST’s CEO Dr Yang Yoonsun Named on the Forbes 2020 List of Asia’s Power Businesswomen2020/09/16MEDIPOST
MEDIPOST enters into new business and accelerates its clinical trials in the U.S. through third-party allotment financing2022/03/17
MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea2021/12/24
MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/10/27
MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/07/30
MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association2021/07/09
